Information Notice 19-04

To: Patient Skin Contamination Events Associated with I-131 MIBG During Neuroblastoma Treatments

Medical Licensees Authorized to Perform Title 10 of the Code of Federal Regulations (10 CFR) 35.200, 300, 400, 600 and 1000 therapeutic procedures.


The Nuclear Regulatory Commission (NRC) recently issued Information Notice (IN) 2019-06 to alert licensees of potential patient contamination risks associated with therapeutic treatments with Iodine-131 (I-131) metaiodobenzylguanidine (MIBG). The Radiologic Health Branch is providing this IN to California licensees who have license authorization to receive and use I-131 for this therapeutic procedure.

The NRC has also issued Information Notice 2019-07 that provides results of an evaluation of medical events and provide strategies to reduce or prevent future medical events. The RHB is providing this IN to California licensees who have license authorization to perform 10 CFR 35.200, 300, 400, 600 and 1000 therapeutic procedures.
The RHB expects licensees to review the information for applicability to your facility and consider actions, as appropriate, to avoid similar problems.


Should you have any questions, please contact Ira Schneider by telephone at (916) 440-7976 or by email at Ira.Schneider@cdph.ca.gov or Gonzalo L. Perez by telephone at (916) 440-7942 or by email at Gonzalo.Perez@cdph.ca.gov.

Sincerely,

*Signature on file*

Gonzalo L. Perez
California Department of Public Health
Radiologic Health Branch